AC

AIHC Capital

Asia, Hong Kong Island, Hong Kong, Central

Description

AIHC is an asset management company focusing on the healthcare sector.

Investor Profile

AIHC Capital has made 4 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (50%)
  • Series D (50%)

Country Focus

  • China (75%)
  • United States (25%)

Industry Focus

  • Biotechnology
  • Biopharma
  • Pharmaceutical
  • Health Care
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does AIHC Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 4
HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 1
HBM Partners
Europe, Zug, Switzerland, Zug
Co-Investments: 1
Catalio Capital Management
North America, New York, United States, New York
Co-Investments: 1
General Catalyst
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
IA
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
Infinitum Partners
North America, Florida, United States, Miami
Co-Investments: 1
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 1
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 2
Boyu Capital
Asia, Beijing, China, Beijing
Co-Investments: 1

What are some of recent deals done by AIHC Capital?

ArriVent Biopharma

Pennsylvania Furnace, Pennsylvania, United States

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

BiotechnologyLife SciencePharmaceutical
Series BDec 29, 2022
Amount Raised: $155,000,000
YS Biopharma

Beijing, Beijing, China

YS Biopharma is a global, fully integrated bio-pharmaceutical company.

BiopharmaBiotechnologyHealth Care
Series BFeb 24, 2021
Amount Raised: $130,000,000
InventisBio

Shanghai, Shanghai, China

InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.

BiopharmaBiotechnologyPharmaceutical
Series DSep 27, 2020
Amount Raised: $147,000,000
Akeso Biopharma

Zhongshan, Anhui, China

Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.

BiopharmaBiotechnologyHealth Care
Series DNov 4, 2019
Amount Raised: $150,000,000